The CMA has closed a competition investigation
into alleged abuse of dominance through loyalty discounting in the
pharmaceutical sector. The CMA has decided not to continue with its year-long investigation
on the grounds that the case is not within its current administrative
priorities. However, it has been at
pains to stress that this does not mean that such cases could not merit
investigation in the future.
Loyalty-inducing rebates have been a
difficult topic at the EU and national level.
Companies who are at risk of being found dominant and competitors who consider
that they are prejudiced by the discounting practices of such firms may
consider that the case was a missed opportunity for the CMA to establish a precedent. The CMA said that the evidence it has
obtained suggests that continuing with its investigation would have had a
limited effect on consumer welfare.
Public authorities have limited resources
and cannot of course investigate every case to a conclusion. The European Commission may also decline to
investigate a case to a full decision on the basis of it not being an EU
priority. This does not mean that the
authority is closing the case due to resource issues alone but that the issues raised
are not considered by it to be a regulatory priority. This can involve the situation where the
evidence gathered does not suggest that there will be a successful outcome.
The CMA has said that it examined the
conduct at issue extensively, including through stakeholder meetings and
information requests. The company under
investigation has not been named yet the investigation has not been without costs
in terms of legal uncertainty and disruption in dealing with the ongoing
scrutiny.
The case comes as a reminder of the often
finely balanced issues to consider in relation to loyalty rebates applied by
dominant firms. Many schemes are
pro-competitive. Others will require a
more detailed assessment. However, until
a competition authority or court makes a definitive decision in this area there
will remain uncertainty in seeking to defend such practices against a
traditional form-based approach and notwithstanding the portent of a more
economics-based approach in the European Commission’s priority guidance.
Statement regarding the CMA's decision to
close an investigation into a suspected breach of competition law in the
pharmaceutical sector on the grounds of administrative priority, 26 June 2015